Chronic lymphocytic leukemia and prognostic factors

Area of Science:

• Hematology
• Oncology
• Clinical Pathology

Background:

• Chronic lymphocytic leukemia (CLL) exhibits variable clinical courses, making prognosis challenging with current staging systems.
• Early-stage CLL patients require reliable prognostic markers to predict disease progression.
• Previous research identified lymphocyte doubling time (LDT), β2-microglobulin (β2-MG), and cytogenetic analysis as potential prognostic indicators.

Purpose of the Study:

• To evaluate a comprehensive range of prognostic factors in patients diagnosed with CLL.
• To determine the relationship between various clinical and laboratory markers and disease outcome in CLL.
• To identify reliable predictors of disease progression and prognosis in CLL.

Main Methods:

• Seventy CLL patients were enrolled and assessed at diagnosis.
• Evaluated prognostic factors included Binet staging, LDT, β2-MG, ESR, LDH, peripheral blood smudge cells, absolute lymphocyte count, and conventional cytogenetics (CC).
• Patients were followed up to ascertain outcomes, and factors were compared against each other and Binet staging.

Main Results:

• β2-microglobulin (β2-MG) levels and lymphocyte doubling time (LDT) showed a significant direct relationship with CLL staging and patient outcome (p<0.0001 and p<0.001, respectively).
• No significant correlation was found between LDH, ESR, smudge cells, or absolute lymphocyte count and disease stage or prognosis.
• Conventional cytogenetic (CC) analysis detected alterations in 19% of patients.

Conclusions:

• Conventional cytogenetics (CC) alone is insufficient for detecting all chromosomal alterations in CLL; fluorescence in situ hybridization (FISH) is recommended.
• Due to the cost and limited availability of FISH, β2-microglobulin (β2-MG) is proposed as a viable and accessible prognostic marker for CLL.
• β2-MG should be considered for integration into the Binet staging system to improve prognostic subgrouping and patient management in CLL.